Mutations in ITPR2 have been reported in various types of solid tumors, including endometrial carcinoma (9.3%) [21], malignant melanoma (6.4%) [22], urothelial carcinoma (7.0%) [23], and rarely in lymphoid neoplasm including DLBCL (3.0–7.5%) [24,25], multiple myeloma (1.5%) [26], CLL (0.2%) [27], and a case with Sezary syndrome [28]. This evidence concerns the gene ITPR2 and urothelial carcinoma.